Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma

MRD validated as a surrogate endpoint for survival in AML

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab